Showing 2756 results
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR ‘Pure-play’ innovative medicines strategy focused on four therapeutic areas and five technology platforms, which offer potential for consistent…
-
Press release /Late-breaking final iDFS analysis from NATALEE investigating Kisqali® (ribociclib) in broad population of patients with stage II and III HR+/HER2- early breast cancer, including those with node-…
-
Press release /Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical dataBreast and gastric cancers are among most common types of cancer, accounting together for nearly half…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-offShares of Sandoz will be listed and…
-
Press release /Key data from the Phase III PSMAfore trial has been selected for a Presidential session; PSMAfore is investigating PluvictoTM (INN: lutetium (177Lu) vipivotide tetraxetan) in the pre-chemotherapy…
-
Press release /Divestment includes Xiidra®, on-market treatment for dry eye disease and additional ophthalmic investigational therapiesNovartis advances strategy of focused portfolio and prioritized therapeutic…
-
Press release /Sandoz shares (SDZ) to be listed and traded on SIX Swiss Exchange; ADRs to be traded on OTCQX®, first trading day October 4, 2023Sandoz to be included in key Swiss market indicesInvestment grade…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Phase III ALIGN study met its primary endpoint, demonstrating superiority of atrasentan vs. placebo in proteinuria reduction at 36-week interim analysis1;…
-
Press release /Les actionnaires approuvent le projet de scission à 100% de Sandoz, l’activité Génériques et Biosimilaires de NovartisLes actionnaires approuvent également une réduction du capital social dans le…
-
Ad hoc release /Ad-hoc-Mitteilung gemäss Art. 53 KR Die Transformation zu einem Unternehmen, das rein auf innovative Medikamente spezialisiert ist, wurde mit dem Spin-off von Sandoz abgeschlossen; die…